🔗 Share this article

This year's prestigious award in medical science has been granted for transformative findings that clarify how the immune system targets harmful infections while protecting the body's own cells.

Three esteemed researchers—Japan's Shimon Sakaguchi and US experts Dr. Brunkow and Fred Ramsdell—share this honor.

The work identified unique "security guards" within the immune system that remove malfunctioning defense cells that could attacking the organism.

The discoveries are now enabling innovative therapies for autoimmune diseases and cancer.

The laureates will divide a prize fund valued at 11 million Swedish kronor.

Crucial Findings

"Their research has been decisive for understanding how the body's defenses functions and why we don't all develop severe autoimmune diseases," stated the head of the award panel.

The team's research explain a fundamental question: How does the immune system protect us from countless infections while leaving our own tissues intact?

The immune system employs white blood cells that scan for indicators of disease, even viruses and bacteria it has not met before.

These defenders employ sensors—known as receptors—that are produced by chance in a vast number of variations.

That gives the defense network the ability to combat a broad range of invaders, but the unpredictability of the process unavoidably produces white blood cells that may target the host.

Security Guards of the Immune System

Researchers previously knew that a portion of these problematic defense cells were destroyed in the thymus—the site where white blood cells develop.

The latest Nobel Prize recognizes the identification of regulatory T-cells—described as the immune system's "security guards"—which patrol the body to disarm any defenders that attack the body's own tissues.

It is known that this mechanism malfunctions in autoimmune diseases such as type-1 diabetes, multiple sclerosis, and RA.

The Nobel panel added, "These findings have established a new field of investigation and accelerated the creation of innovative treatments, for instance for cancer and immune disorders."

In malignancies, regulatory T-cells prevent the body from fighting the growth, so studies are focused on lowering their quantity.

In autoimmune diseases, experiments are testing increasing T-reg cells so the body is not under attack. A similar method could also be useful in reducing the risks of transplanted organ failure.

Innovative Studies

Professor Shimon Sakaguchi, of Osaka University, performed tests on rodents that had their immune gland extracted, leading to self-attack conditions.

He demonstrated that injecting immune cells from other mice could prevent the illness—implying there was a system for blocking defenders from attacking the host.

Mary Brunkow, from the a research center in a US city, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were studying an inherited immune disorder in mice and people that resulted in the identification of a genetic factor critical for how regulatory T-cells function.

"Their groundbreaking research has revealed how the immune system is kept in check by regulatory T cells, stopping it from accidentally targeting the body's own tissues," commented a leading physiology specialist.

"The research is a remarkable example of how fundamental physiological research can have far-reaching consequences for public health."